TRON Group Inc.

Equities

TGRP

US8970121005

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 14:55:51 2024-02-09 EST			5-day change	1st Jan Change
0.6 ^USD	-1.32%		-.--%	-1.32%

2022	TRON Group Inc. Appoints James D. Talton as President, Secretary/Treasurer and Director	CI
2022	TRON Group Inc. Appoints James D. Talton as Chief Executive Officer	CI

TRON Group Inc. acquired Digital Engineering Corporation.

July 07, 2021

TRON Group Inc. (OTCPK:TGRP) acquired Digital Engineering Corporation on July 8, 2021. Digital Engineering Corporation will also be managing TRON's subsidiary, American Crypto Services, Inc., which own a crypto mining facility in the Boise Valley of Idaho. TRON Group Inc. (OTCPK:TGRP) completed the acquisition of Digital Engineering Corporation on July 8, 2021.

Latest news about TRON Group Inc.

TRON Group Inc. Appoints James D. Talton as President, Secretary/Treasurer and Director	22-08-11	CI
TRON Group Inc. Appoints James D. Talton as Chief Executive Officer	22-08-11	CI
TRON Group Inc. entered into a definitive agreement to acquire Nanopharmaceutics, Inc.	22-08-10	CI
TRON Group Inc. acquired Digital Engineering Corporation.	21-07-07	CI
TRON Group Inc. acquired American Crypto Systems, Inc.	21-07-05	CI
Talk Focus Sdn Bhd acquired TRON Group Inc. in a reverse merger transaction.	18-01-25	CI
Talk Focus Sdn Bhd and another buyer completed the acquisition of IEC Technology Co., Ltd. from The International Engineering Public Company Limited.	14-04-04	CI
Talk Focus Sdn Bhd and another buyer agreed to acquire IEC Technology Co., Ltd. from The International Engineering Public Company Limited for THB 11.7 million.	14-03-25	CI

Chart TRON Group Inc.

Duration

Period

More charts

Company Profile

Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company. The Company is developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. The Company is developing a clinical pipeline of oral, topical and injectable small molecule drug candidates to treat human cancer, central nervous system (CNS) disorders and infectious diseases. The pipeline includes 10 clinical-stage proprietary and partnered programs including Triapine, Ammonium Tetrathiomolybdate and Aza-TdC, targeting cancer; NanoBUP, PRX-3140, NP-18-2, and NP-18-3, targeting CNS; and Ramoplanin and NanoDOX, targeting infectious disease. Leveraging its expertise in nanoparticle and fine-particle formulations, the Company is focused on formulation development aimed at improving drug absorption and stability. Triapine is a synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
TRON GROUP INC.	-1.32%	104M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs